Syndax Pharmaceuticals SNDX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$285.42M+10.5% | -$318.76M-52.3% | -$209.36M-40.2% | -$149.34M-699% | ||
| $47.5M+10.4% | $43.03M+39.0% | $30.95M+93.2% | $16.02M+20.3% | ||
| $229K+663% | $30K— | $0— | $0— | ||
| $30.39M+300% | $7.6M— | $0— | $0— | ||
| $32.09M+8,668% | $366K— | $0— | $0— | ||
| —— | $1.67M— | —— | -$1.32M— | ||
| $42.17M+120% | $19.14M+28.7% | $14.87M— | —— | ||
| $14.54M— | —— | —— | —— | ||
| —— | -$463K— | $0— | —— | ||
| $6.44M— | —— | $0— | $0— | ||
| -$322.98M-17.5% | -$274.9M-71.2% | -$160.6M-20.1% | -$133.68M-559% | ||
| $195.81M-64.8% | $557.05M+57.1% | $354.61M-28.4% | $495.35M+68.1% | ||
| $486.03M+44.1% | $337.28M-28.6% | $472.22M+52.9% | $308.93M+21.6% | ||
| $290.04M— | —— | —— | -$186.19M— | ||
| $13.68M-96.1% | $353.37M+33.8% | $264.13M+42.2% | $185.78M+56.8% | ||
| —— | —— | $223.87M+249% | -$150.59M— | ||
| $10.75M-20.2% | $13.47M-9.0% | $14.8M+338% | $3.38M+625% | ||
| $229K+663% | $30K— | $0— | $0— | ||
| $6K-25.0% | $8K-33.3% | $12K-63.6% | $33K-23.3% | ||
| $6.44M— | —— | $0— | $0— | ||
| $42.17M+120% | $19.14M+28.7% | $14.87M— | —— | ||
| -$42.98M-458% | $12M— | —— | —— | ||
| $14.54M— | —— | —— | —— | ||
| $163K— | $0— | $0— | —— | ||
| $946K-4.3% | $989K+33.8% | $739K+75.5% | $421K+1.9% | ||
| $3.67M— | —— | $0— | —— | ||
| $195.81M-64.8% | $557.05M+57.1% | $354.61M-28.4% | $495.35M+68.1% | ||
| $486.03M+44.1% | $337.28M-28.6% | $472.22M+52.9% | $308.93M+21.6% | ||
| $0-100% | $343.65M— | $0— | $0— | ||
| $1.62M-5.7% | $1.72M+88.5% | $910K+127% | $401K+9.3% | ||
| $0— | $0-100% | $250K+90.8% | $131K— | ||
| $0-100% | $1.52M— | $0— | $0— | ||
| -$323.17M-17.6% | -$274.9M-71.2% | -$160.6M-20.1% | -$133.68M-561% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Syndax Pharmaceuticals's cash flow data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.